…[the] 155-participant study failed to show that a 15-day course helped more than a placebo in reducing fatigue, brain fog, shortness of breath, body aches, or gastrointestinal or cardiovascular symptoms. Trial participants, on average, had been sick more than 16 months before enrolling in the trial.
This result does not affect PFE’s $3B guidance for 2024 Paxlovid sales (#msg-174337779).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”